[en] [en] BACKGROUND: Maternal pertussis vaccination with Tdap vaccine is recommended to protect newborns from severe postnatal infection. HIV-exposed uninfected (HEU) infants have a higher incidence of pertussis infection and may particularly benefit from maternal immunization. The impact of HIV infection on the quality of IgG and memory B cell (MBC) responses to Tdap vaccination in pregnant women (PW) living with HIV (PWH) is unknown.
METHODS: In this observational study, humoral immune responses to Tdap vaccination, including IgG levels, Fc-dependent effector functions, and MBC frequencies, were measured before and after vaccination in 40 PWH and 42 HIV-uninfected PW. Placental transfer of IgG and avidity were assessed in cord blood (CB). Soluble and cellular immune activation markers were quantified at baseline.
FINDINGS: One month after vaccination, PWH had lower frequencies of MBC compared with HIV-uninfected PW. At delivery, PWH had attenuated pertussis-specific IgG levels and Fc-dependent effector functions. Reduced levels of maternal vaccine polyfunctional IgG and IgG avidity were transferred to HEU as compared to HIV-unexposed newborns. After adjustment with ethnicity, maternal antibody levels and gestational age at vaccination, HIV infection was independently associated with decreased levels of PT specific-IgG in CB. Both maternal and neonatal pertussis-specific IgG responses as well as PT-specific IgG avidity were inversely correlated with maternal sCD14 levels before vaccination among PWH.
INTERPRETATION: Maternal HIV infection is associated with attenuated humoral immune responses to Tdap vaccination that correlate with sCD14. Suboptimal transfer of maternal immunity may further increase the risk of severe pertussis infection in HEU infants.
FUNDING: This work was supported by IRIS Fund managed by the Foundation Roi Baudouin [2017J1820690206902], Association Vésale pour la Recherche Médicale and the Medical Council of CHU Saint-Pierre and has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, under Award No. U19AI145825. N.D. is a clinical researcher and A.M. is Research Director at the Fonds de la Recherche Scientifique (F.R.S.-FNRS), Belgium. M.E.A. was partially supported by NIHNIAID1U19AI14825. This article is published with the support of the Fondation Universitaire of Belgium.
Disciplines :
Immunology & infectious disease
Author, co-author :
Taton, Martin ; Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium
Willems, Fabienne; Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium
Widomski, Cyprien; European Plotkin Institute for Vaccinology, Université Libre de Bruxelles (ULB), , Brussels, Belgium
Martin, Charlotte; Department of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
Jiang, Yiwei; European Plotkin Institute for Vaccinology, Université Libre de Bruxelles (ULB), , Brussels, Belgium
Renard, Katty; Clinical Research Unit, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
Konopnicki, Deborah; Department of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
Cogan, Alexandra; Department of Gynecology and Obstetrics, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
Necsoi, Coca; Department of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
Matagne, André ; Université de Liège - ULiège > Département des sciences de la vie > Enzymologie et repliement des protéines
De Wit, Stéphane; Department of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
Ackerman, Margaret E; Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA, Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
Marchant, Arnaud; European Plotkin Institute for Vaccinology, Université Libre de Bruxelles (ULB), , Brussels, Belgium
Dauby, Nicolas; Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium, Department of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium. Electronic address: Nicolas.Dauby@stpierre-bru.be
This work was supported by IRIS Fund managed by the Foundation Roi Baudouin [2017J1820690206902], Association V\u00E9sale pour la Recherche M\u00E9dicale and the Medical Council of CHU Saint-Pierre and has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, under Award No. U19AI145825. This article is published with the support of the Fondation Universitaire of Belgium.This work was supported by IRIS Fund managed by the Foundation Roi Baudouin [2017J1820690206902], Association V\u00E9sale pour la Recherche M\u00E9dicale and the Medical Council of CHU Saint-Pierre and has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, under Award No. U19AI145825. N.D. is a clinical researcher and A.M. is Research Director at the Fonds de la Recherche Scientifique (F.R.S.-FNRS), Belgium. M.E.A. was partially supported by NIH NIAID 1U19AI14825. This article is published with the support of the Fondation Universitaire of Belgium.We would like to thank all pregnant women who participated in this study and all clinical nurses for their help with patients recruitment. We thank Marc Delforge and ULB HeLSci\u2014BIOPS experts for their contributions to the statistical analyses. We would like to thank the Robotein\u00AE platform at the BE Instruct-ERIC Center for providing access to the HTX Octet and the Microlab STAR liquid handling station. This work was supported by IRIS Fund managed by the Foundation Roi Baudouin [2017J1820690206902], Association V\u00E9sale pour la Recherche M\u00E9dicale and the Medical Council of CHU Saint-Pierre and has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, under Award No. U19AI145825. This article is published with the support of the Fondation Universitaire of Belgium.Y.J reports support from the F.R.S-FNRS. N.D. reports grant support from MSD, honoraria from Boerhingher Ingelheim, and support for attending meetings and/or travel from MSD, ViiV healthcare and Eumedica, all unrelated to the present work. D.K reports honoraria from MSD, ViiV, Janssens, support for attending meetings and/or travel from Gilead, Pfizer, MSD, ViiV and Janssens, participation on advisory board for MSD, all unrelated to the present work. M.A. reports grants from NIH, Bill and Melinda Gates Foundation, SD Ireland Foundation, consulting fees from Seromyx systems and support for attending meetings and/or travel from Keystone conferences, Bill and Melinda Gates
Mother-to-child transmission of HIV n.d. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/mother-to-child-transmission-of-hiv. (Accessed 27 June 2022)
Adler, C., Haelterman, E., Barlow, P., Marchant, A., Levy, J., Goetghebuer, T., Severe infections in HIV-exposed uninfected infants born in a European country. PLoS One, 10, 2015, e0135375, 10.1371/journal.pone.0135375.
Dauby, N., Chamekh, M., Melin, P., Slogrove, A.L., Goetghebuer, T., Increased risk of group B Streptococcus invasive infection in HIV-exposed but uninfected infants: a review of the evidence and possible mechanisms. Front Immunol, 7, 2016, 505.
Locht, C., Mielcarek, N., New pertussis vaccination approaches: en route to protect newborns?. FEMS Immunol Med Microbiol 66 (2012), 121–133, 10.1111/j.1574-695X.2012.00988.x.
Muloiwa, R., Kagina, B.M., Engel, M.E., Hussey, G.D., The burden of laboratory-confirmed pertussis in low- and middle-income countries since the inception of the Expanded Programme on Immunisation (EPI) in 1974: a systematic review and meta-analysis. BMC Med, 18, 2020, 233, 10.1186/s12916-020-01699-3.
Bengtson, A.M., Sanfilippo, A.M., Hughes, B.L., Savitz, D.A., Maternal immunisation to improve the health of HIV-exposed infants. Lancet Infect Dis 19 (2019), e120–e131, 10.1016/S1473-3099(18)30545-0.
Report 8754 - maternal immunisation, 2020, FPS Public Health https://www.health.belgium.be/en/report-8754-maternal-immunisation. (Accessed 14 January 2022)
Liang, J.L., Tiwari, T., Moro, P., et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 67 (2018), 1–44, 10.15585/mmwr.rr6702a1.
Eberhardt, C.S., Blanchard-Rohner, G., Lemaître, B., et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis 62 (2016), 829–836, 10.1093/cid/ciw027.
Simister, N.E., Placental transport of immunoglobulin G. Vaccine 21 (2003), 3365–3369, 10.1016/s0264-410x(03)00334-7.
Dauby, N., Gagneux-Brunon, A., Martin, C., Mussi-Pinhata, M.M., Goetghebuer, T., Maternal immunization in women living with HIV. AIDS 38 (2024), 137–144, 10.1097/QAD.0000000000003758.
Zicari, S., Sessa, L., Cotugno, N., et al. Immune activation, inflammation, and non-AIDS Co-morbidities in HIV-infected patients under long-term ART. Viruses, 11, 2019, 200, 10.3390/v11030200.
Sokoya, T., Steel, H.C., Nieuwoudt, M., Rossouw, T.M., HIV as a cause of immune activation and immunosenescence. Mediators Inflamm, 2017, 2017, 6825493, 10.1155/2017/6825493.
Moir, S., Fauci, A.S., B cells in HIV infection and disease. Nat Rev Immunol 9 (2009), 235–245, 10.1038/nri2524.
Tanko, R.F., Soares, A.P., Müller, T.L., et al. Effect of antiretroviral therapy on the memory and activation profiles of B cells in HIV-infected African women. J Immunol 198 (2017), 1220–1228, 10.4049/jimmunol.1601560.
Liechti, T., Kadelka, C., Braun, D.L., et al. Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells. J Exp Med 216 (2019), 2071–2090, 10.1084/jem.20181124.
Lange, C.G., Lederman, M.M., Medvik, K., et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 17 (2003), 2015–2023, 10.1097/00002030-200309260-00002.
Alonso, S., Vidal, M., Ruiz-Olalla, G., et al. Reduced placental transfer of antibodies against a wide range of microbial and vaccine antigens in HIV-infected women in Mozambique. Front Immunol, 12, 2021, 614246, 10.3389/fimmu.2021.614246.
Dangor, Z., Nunes, M.C., Kwatra, G., Lala, S.G., Madhi, S.A., Vaccination of HIV-infected pregnant women: implications for protection of their young infants. Trop Dis Travel Med Vaccines, 3, 2017, 1, 10.1186/s40794-016-0044-7.
Jones, C.E., Naidoo, S., De Beer, C., Esser, M., Kampmann, B., Hesseling, A.C., Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA 305 (2011), 576–584, 10.1001/jama.2011.100.
Taylor, S.A., Sharma, S., Remmel, C.A.L., et al. HIV-associated alterations of the biophysical features of maternal antibodies correlate with their reduced transfer across the placenta. J Infect Dis 226:8 (2022), 1441–1450, 10.1093/infdis/jiac222.
Ackerman, M.E., Crispin, M., Yu, X., et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 123 (2013), 2183–2192, 10.1172/JCI65708.
Ljunggren, K., Broliden, P.A., Morfeldt-Månson, L., Jondal, M., Wahren, B., IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol 73 (1988), 343–347.
Brown, E.P., Licht, A.F., Dugast, A.-S., et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J Immunol Methods 386 (2012), 117–123, 10.1016/j.jim.2012.09.007.
Perez, L.G., Martinez, D.R., deCamp, A.C., et al. V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS One, 12, 2017, e0180720, 10.1371/journal.pone.0180720.
Ackerman, M.E., Moldt, B., Wyatt, R.T., et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 366 (2011), 8–19, 10.1016/j.jim.2010.12.016.
Masseria, C., Martin, C.K., Krishnarajah, G., Becker, L.K., Buikema, A., Tan, T.Q., Incidence and burden of pertussis among infants less than 1 year of age. Pediatr Infect Dis J 36 (2017), e54–e61, 10.1097/INF.0000000000001440.
Ruck, C.E., Smolen, K.K., Effect of maternal HIV infection on infant development and outcomes. Front Virol, 2, 2022, 885246.
Taton, M., Willems, F., Widomski, C., et al. Impact of pregnancy on polyfunctional IgG and memory B cell responses to Tdap immunization. Vaccine 41 (2023), 4009–4018.
de Armas, L.R., Pallikkuth, S., George, V., et al. Reevaluation of immune activation in the era of cART and an aging HIV-infected population. JCI Insight, 2, 2017, e95726, 10.1172/jci.insight.95726.
Dauby, N., Sartori, D., Kummert, C., et al. Limited effector memory B-cell response to envelope glycoprotein B during primary human cytomegalovirus infection. J Infect Dis 213 (2016), 1642–1650, 10.1093/infdis/jiv769.
Fischinger, S., Fallon, J.K., Michell, A.R., et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J Immunol Methods, 473, 2019, 112630, 10.1016/j.jim.2019.07.002.
Karsten, C.B., Mehta, N., Shin, S.A., et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. J Immunol Methods 471 (2019), 46–56, 10.1016/j.jim.2019.05.006.
Pannus, P., Neven, K.Y., De Craeye, S., et al. Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes. Clin Infect Dis 75:1 (2021), e695–e704, 10.1093/cid/ciab998.
Maertens, K., Caboré, R.N., Huygen, K., Hens, N., Van Damme, P., Leuridan, E., Pertussis vaccination during pregnancy in Belgium: results of a prospective controlled cohort study. Vaccine 34 (2016), 142–150, 10.1016/j.vaccine.2015.10.100.
Barkoff, A.-M., Gröndahl-Yli-Hannuksela, K., Vuononvirta, J., Mertsola, J., Kallonen, T., He, Q., Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine 30 (2012), 6897–6902, 10.1016/j.vaccine.2012.09.003.
Avanzini, M., Pignatti, P., Chirico, G., Gasparoni, A., Jalil, F., Hanson, L., Placental transfer favours high avidity IgG antibodies. Acta Paediatr 87 (1998), 180–185, 10.1111/j.1651-2227.1998.tb00972.x.
Fernández-Cano, M.I., Armadans, Gil L., Campins, Martí M., Cost-benefit of the introduction of new strategies for vaccination against pertussis in Spain: cocooning and pregnant vaccination strategies. Vaccine 33 (2015), 2213–2220, 10.1016/j.vaccine.2015.03.045.
Nunes, M.C., Cutland, C.L., Dighero, B., et al. Kinetics of hemagglutination-inhibiting antibodies following maternal influenza vaccination among mothers with and those without HIV infection and their infants. J Infect Dis 212 (2015), 1976–1987, 10.1093/infdis/jiv339.
Abzug, M.J., Nachman, S.A., Muresan, P., et al. Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin Infect Dis 56 (2013), 1488–1497, 10.1093/cid/cit057.
Richardson, K., Weinberg, A., Reduced immunogenicity of influenza vaccines in HIV-infected compared with uninfected pregnant women is associated with regulatory T cells. AIDS 25 (2011), 595–602, 10.1097/QAD.0b013e32834411a8.
Madhi, S.A., Cutland, C.L., Kuwanda, L., et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 371 (2014), 918–931, 10.1056/NEJMoa1401480.
Bashir, M.F., Elechi, H.A., Ashir, M.G., et al. Neonatal tetanus immunity in Nigeria: the effect of HIV infection on serum levels and transplacental transfer of antibodies. J Trop Med, 2016, 2016, 7439605, 10.1155/2016/7439605.
Heyderman, R.S., Madhi, S.A., French, N., et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis 16 (2016), 546–555, 10.1016/S1473-3099(15)00484-3.
Nunes, M.C., Tamblyn, A., Jose, L., et al. Immunogenicity of tetanus, diphtheria and acellular pertussis vaccination among pregnant women living with and without HIV. AIDS 37 (2023), 2305–2310, 10.1097/QAD.0000000000003731.
Higgs, R., Higgins, S.C., Ross, P.J., Mills, K.H.G., Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 5 (2012), 485–500, 10.1038/mi.2012.54.
Motsoeneng, B.M., Dhar, N., Nunes, M.C., et al. Influenza vaccination results in differential hemagglutinin stalk-specific Fc-mediated functions in individuals living with or without HIV. Front Immunol, 13, 2022, 873191, 10.3389/fimmu.2022.873191.
Palmeira, P., Quinello, C., Silveira-Lessa, A.L., Zago, C.A., Carneiro-Sampaio, M., IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol, 2012, 2012, 985646, 10.1155/2012/985646.
Oguti, B., Ali, A., Andrews, N., et al. The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine 40 (2022), 450–458, 10.1016/j.vaccine.2021.12.007.
Barkoff, A.-M., Knuutila, A., Mertsola, J., He, Q., Evaluation of anti-PT antibody response after pertussis vaccination and infection: the importance of both quantity and quality. Toxins, 13, 2021, 508, 10.3390/toxins13080508.
Thierry-Carstensen, B., Dalby, T., Stevner, M.A., Robbins, J.B., Schneerson, R., Trollfors, B., Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults—a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine 31 (2013), 5178–5191.
Nguyen, A.W., DiVenere, A.M., Papin, J.F., Connelly, S., Kaleko, M., Maynard, J.A., Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons. Sci Adv, 6, 2020, eaay9258, 10.1126/sciadv.aay9258.
Healy, C.M., Rench, M.A., Swaim, L.S., et al. Association between third-trimester Tdap immunization and neonatal pertussis antibody concentration. JAMA 320 (2018), 1464–1470, 10.1001/jama.2018.14298.
Cumberland, P., Shulman, C.E., Maple, P.A.C., et al. Maternal HIV infection and placental malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis 196 (2007), 550–557, 10.1086/519845.
Jones, C., Pollock, L., Barnett, S.M., Battersby, A., Kampmann, B., Specific antibodies against vaccine-preventable infections: a mother–infant cohort study. BMJ Open, 3, 2013, e002473, 10.1136/bmjopen-2012-002473.
Dolatshahi, S., Butler, A.L., Siedner, M.J., et al. Altered maternal antibody profiles in women with human immunodeficiency virus drive changes in transplacental antibody transfer. Clin Infect Dis 75 (2022), 1359–1369, 10.1093/cid/ciac156.
Le Doare, K., Allen, L., Kampmann, B., et al. Anti-group B Streptococcus antibody in infants born to mothers with human immunodeficiency virus (HIV) infection. Vaccine 33 (2015), 621–627, 10.1016/j.vaccine.2014.12.025.
Abu Raya, B., Bamberger, E., Almog, M., Peri, R., Srugo, I., Kessel, A., Immunization of pregnant women against pertussis: the effect of timing on antibody avidity. Vaccine 33 (2015), 1948–1952, 10.1016/j.vaccine.2015.02.059.
Hu, Z., Luo, Z., Wan, Z., et al. HIV-associated memory B cell perturbations. Vaccine 33 (2015), 2524–2529, 10.1016/j.vaccine.2015.04.008.
Malaspina, A., Moir, S., Orsega, S.M., et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 191 (2005), 1442–1450, 10.1086/429298.
Parmigiani, A., Alcaide, M.L., Freguja, R., et al. Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation. PLoS One, 8, 2013, e79816, 10.1371/journal.pone.0079816.
George, V.K., Pallikkuth, S., Parmigiani, A., et al. HIV infection worsens age-associated defects in antibody responses to influenza vaccine. J Infect Dis 211 (2015), 1959–1968, 10.1093/infdis/jiu840.
Bruno, G., Saracino, A., Monno, L., Angarano, G., The revival of an “Old” marker: CD4/CD8 ratio. AIDS Rev 19 (2017), 81–88.
Avelino-Silva, V.I., Miyaji, K.T., Hunt, P.W., et al. CD4/CD8 ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients. PLoS Neglected Trop Dis, 10, 2016, e0005219, 10.1371/journal.pntd.0005219.
Alrubayyi, A., Gea-Mallorquí, E., Touizer, E., et al. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. Nat Commun, 12, 2021, 5839, 10.1038/s41467-021-26137-7.
Feng, Y., Zhang, Y., He, Z., et al. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study. eClinicalMedicine, 43, 2022, 10.1016/j.eclinm.2021.101226.
Eberhardt, C.S., Blanchard-Rohner, G., Lemaître, B., et al. Pertussis antibody transfer to preterm neonates after second- versus third-trimester maternal immunization. Clin Infect Dis 64 (2017), 1129–1132, 10.1093/cid/cix046.
Germain, R.S., Bossard, E.L., Corey, L., Sholukh, A.M., Serum concentration of antigen-specific IgG can substantially bias interpretation of antibody-dependent phagocytosis assay readout. iScience, 26, 2023, 107527.
Jennewein, M.F., Kosikova, M., Noelette, F.J., et al. Functional and structural modifications of influenza antibodies during pregnancy. iScience, 25(4), 2021, 104088, 10.1101/2021.05.18.444722.
Atyeo, C., DeRiso, E.A., Davis, C., et al. COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. Sci Transl Med, 13, 2021, eabi8631, 10.1126/scitranslmed.abi8631.
